Camurus AB (publ) (CAMRF)
USD 50.97
(0.0%)
USD 50.97
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.16 Billion SEK | -116.07% |
| 2022 | -539.32 Million SEK | -39.75% |
| 2021 | -385.91 Million SEK | 11.55% |
| 2020 | -436.31 Million SEK | -31.65% |
| 2019 | -331.41 Million SEK | -146.63% |
| 2018 | -134.37 Million SEK | 57.28% |
| 2017 | -314.52 Million SEK | 38.16% |
| 2016 | -508.59 Million SEK | 28.98% |
| 2015 | -716.09 Million SEK | -1278642.86% |
| 2014 | -56 Thousand SEK | -1020.0% |
| 2013 | -5000.00 SEK | -66.67% |
| 2012 | -3000.00 SEK | -50.0% |
| 2011 | -2000.00 SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -2.25 Billion SEK | -93.17% |
| 2024 Q2 | -2.54 Billion SEK | -13.11% |
| 2023 Q4 | -1.16 Billion SEK | -3.26% |
| 2023 FY | -1.16 Billion SEK | -116.07% |
| 2023 Q1 | -561.82 Million SEK | -4.17% |
| 2023 Q2 | -627.31 Million SEK | -11.66% |
| 2023 Q3 | -1.12 Billion SEK | -79.9% |
| 2022 Q1 | -375.86 Million SEK | 2.61% |
| 2022 FY | -539.32 Million SEK | -39.75% |
| 2022 Q3 | -494.4 Million SEK | -21.83% |
| 2022 Q4 | -539.32 Million SEK | -9.08% |
| 2022 Q2 | -405.83 Million SEK | -7.97% |
| 2021 Q4 | -385.91 Million SEK | 3.53% |
| 2021 Q3 | -400.02 Million SEK | -0.27% |
| 2021 FY | -385.91 Million SEK | 11.55% |
| 2021 Q1 | -403.6 Million SEK | 7.5% |
| 2021 Q2 | -398.95 Million SEK | 1.15% |
| 2020 Q3 | -451.98 Million SEK | -129.6% |
| 2020 FY | -436.31 Million SEK | -31.65% |
| 2020 Q2 | -196.85 Million SEK | 25.73% |
| 2020 Q1 | -265.04 Million SEK | 20.03% |
| 2020 Q4 | -436.31 Million SEK | 3.47% |
| 2019 Q3 | -166.11 Million SEK | 35.12% |
| 2019 FY | -331.41 Million SEK | -146.63% |
| 2019 Q4 | -331.41 Million SEK | -99.5% |
| 2019 Q2 | -256.03 Million SEK | 32.4% |
| 2019 Q1 | -378.76 Million SEK | -181.87% |
| 2018 Q4 | -134.37 Million SEK | 37.89% |
| 2018 FY | -134.37 Million SEK | 57.28% |
| 2018 Q1 | -266.63 Million SEK | 15.23% |
| 2018 Q2 | -199.09 Million SEK | 25.33% |
| 2018 Q3 | -216.34 Million SEK | -8.67% |
| 2017 FY | -314.52 Million SEK | 38.16% |
| 2017 Q1 | -463.8 Million SEK | 8.81% |
| 2017 Q2 | -413.36 Million SEK | 10.88% |
| 2017 Q3 | -369.74 Million SEK | 10.55% |
| 2017 Q4 | -314.52 Million SEK | 14.94% |
| 2016 Q4 | -508.59 Million SEK | 1.86% |
| 2016 Q2 | -548.98 Million SEK | 4.01% |
| 2016 FY | -508.59 Million SEK | 28.98% |
| 2016 Q3 | -518.24 Million SEK | 5.6% |
| 2016 Q1 | -571.91 Million SEK | 20.13% |
| 2015 Q1 | 56 Thousand SEK | 200.0% |
| 2015 Q4 | -716.09 Million SEK | -537.4% |
| 2015 Q3 | -112.34 Million SEK | 0.0% |
| 2015 FY | -716.09 Million SEK | -1278642.86% |
| 2014 Q4 | -56 Thousand SEK | 0.0% |
| 2014 FY | -56 Thousand SEK | -1020.0% |
| 2013 FY | -5000.00 SEK | -66.67% |
| 2012 FY | -3000.00 SEK | -50.0% |
| 2011 FY | -2000.00 SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 100957.171% |
| CSL Limited | 10.52 Billion USD | 111.071% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 7492.838% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 28398.354% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 290092.758% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 2823.186% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -18384.076% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 125784.922% |
| Mesoblast Limited | 55.85 Million USD | 2186.232% |
| Marizyme, Inc. | 18.56 Million USD | 6375.681% |
| Genus plc | 190.6 Million USD | 711.402% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 52220.777% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 96100.043% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 171472.5% |
| ContraFect Corporation | -6.02 Million USD | -19238.417% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 865624.105% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | 7.67 Million USD | 15292.358% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 21280.571% |
| MultiCell Technologies, Inc. | 90.04 USD | 1294239327.01% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -158669.473% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 9101.491% |
| EV Biologics, Inc. | 1.36 Million USD | 85286.967% |
| Q BioMed Inc. | 4.06 Million USD | 28802.727% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 3914.011% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 115741.014% |
| Biomind Labs Inc. | 711.4 Thousand USD | 163907.945% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 9199.479% |
| Skye Bioscience, Inc. | -5.72 Million USD | -20268.009% |
| SQZ Biotechnologies Company | -36.23 Million USD | -3115.776% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 833647.681% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 20731.315% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 52071.985% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 5865771.717% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 187342.996% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 1161.285% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 135565.875% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 53022.028% |
| GB Sciences, Inc. | 1.74 Million USD | 66792.745% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -633963.704% |
| argenx SE | -2.02 Billion USD | 42.562% |
| HST Global, Inc. | 96.79 Thousand USD | 1204043.467% |
| Halberd Corporation | 144.72 Thousand USD | 805327.299% |
| Enzolytics Inc. | 981.65 Thousand USD | 118810.933% |
| Resverlogix Corp. | 6.45 Million USD | 18164.378% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -173032.082% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 2782.997% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 2024.715% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | -2378.799% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 58384.368% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 16580.521% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 324064.583% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 43123.206% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -13082.631% |
| AVAX Technologies, Inc. | -5.9 Million USD | -19640.677% |
| ONE Bio Corp. | 9.04 Million USD | 12990.802% |
| Zenith Capital Corp. | 10.06 Thousand USD | 11579322.973% |
| Genscript Biotech Corporation | -1.06 Billion USD | -9.799% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 581510.653% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 48939.748% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 708470.363% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -6361582.498% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 565200.355% |
| Agentix Corp. | 37.63 Thousand USD | 3096836.733% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -253.1 Thousand USD | -460320.305% |
| Helix BioMedix, Inc. | -2.57 Million USD | -45243.132% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 5847.352% |
| BioStem Technologies, Inc. | 4.47 Million USD | 26158.366% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 579135.945% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -88956617.557% |
| LadRx Corporation | -2.03 Million USD | -57123.213% |
| Cell Source, Inc. | 9.23 Million USD | 12722.797% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -5710077.381% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 183568.757% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 183568.757% |
| NovAccess Global Inc. | 2.17 Million USD | 53593.308% |
| Affymax, Inc. | -5.59 Million USD | -20720.672% |
| Itoco Inc. | 228.3 Thousand USD | 510528.155% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 857031.811% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 23608.836% |
| CytoDyn Inc. | 20.26 Million USD | 5851.323% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -180113192.117% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -12573165.547% |
| Qrons Inc. | 351.42 Thousand USD | 331700.304% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 15222.407% |
| SYBLEU INC | 473.71 Thousand USD | 246099.274% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -466742.801% |
| Rebus Holdings, Inc. | 305 Thousand USD | 382176.393% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 26246.001% |
| Mobile Lads Corp. | 484.23 Thousand USD | 240755.925% |
| International Stem Cell Corporation | 2.59 Million USD | 45093.552% |
| Bioxytran, Inc. | 1.89 Million USD | 61468.393% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 1867231.848% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 53533.582% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 34035.149% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 13724.845% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 150931.276% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -93126.64% |
| Neutra Corp. | 52.18 Thousand USD | 2233094.807% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -46719.325% |
| PureTech Health plc | -167.19 Million USD | -596.982% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -475724.8% |
| IXICO plc | -4.44 Million USD | -26119.152% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 8915.591% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 2224.543% |
| CSL Limited | 10.52 Billion USD | 111.071% |
| Cellectis S.A. | -43.81 Million USD | -2559.432% |